QRG Capital Management Inc. Has $1.12 Million Position in argenex SE $ARGX

QRG Capital Management Inc. lifted its stake in argenex SE (NASDAQ:ARGX) by 65.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,530 shares of the company’s stock after acquiring an additional 607 shares during the quarter. QRG Capital Management Inc.’s holdings in argenex were worth $1,117,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Abound Wealth Management raised its stake in shares of argenex by 3,200.0% during the 4th quarter. Abound Wealth Management now owns 33 shares of the company’s stock worth $28,000 after purchasing an additional 32 shares in the last quarter. Sound Income Strategies LLC acquired a new position in argenex in the fourth quarter worth approximately $28,000. Ameriflex Group Inc. bought a new position in argenex during the third quarter valued at approximately $32,000. Sunbelt Securities Inc. bought a new position in argenex during the third quarter valued at approximately $36,000. Finally, Aventura Private Wealth LLC acquired a new stake in argenex in the fourth quarter valued at approximately $38,000. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ARGX has been the topic of several analyst reports. HC Wainwright reissued a “buy” rating and set a $940.00 target price on shares of argenex in a research report on Thursday, June 25th. Guggenheim raised their price objective on argenex from $1,120.00 to $1,135.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Royal Bank Of Canada boosted their target price on argenex from $890.00 to $945.00 and gave the stock an “outperform” rating in a report on Tuesday. Wedbush reiterated an “outperform” rating and set a $1,000.00 price target on shares of argenex in a report on Thursday, June 11th. Finally, Morgan Stanley lifted their price target on shares of argenex from $1,170.00 to $1,180.00 and gave the company an “overweight” rating in a research report on Wednesday, June 24th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,037.61.

argenex Price Performance

Shares of argenex stock opened at $915.30 on Thursday. argenex SE has a 52-week low of $538.91 and a 52-week high of $953.58. The firm has a market capitalization of $56.92 billion, a PE ratio of 40.75, a price-to-earnings-growth ratio of 1.14 and a beta of 0.45. The company’s fifty day moving average price is $848.98 and its two-hundred day moving average price is $812.23.

argenex (NASDAQ:ARGX) last issued its earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. The business had revenue of $1.31 billion for the quarter. argenex had a net margin of 31.31% and a return on equity of 44.37%. Analysts predict that argenex SE will post 26.27 earnings per share for the current fiscal year.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.